Page 5 - மருந்து கட்டுப்படுத்தி ஜநரல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ZyCoV-D: India s Homegrown Three-Dose Covid-19 Vaccine For Anyone Over 12, Approved For Emergency Use

ZyCoV-D: India s Homegrown Three-Dose Covid-19 Vaccine For Anyone Over 12, Approved For Emergency Use
swarajyamag.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from swarajyamag.com Daily Mail and Mail on Sunday newspapers.

Zydus cadilaNarendra modiPankajr patelDavidb weinersaysAatmanirbhar bharatSharvil patelMichelea kutzlerMission covid surakshaDepartment of biotechnologyBiotechnology industry research assistance councilCadila healthcare ltdRussia gamaleya instituteSerum institute of indiaExpert committeeDrug controller generalHyderabad based bharat biotech

J&J vaccine: Johnson & Johnson seeks nod for trial of single-dose vaccine on adolescents in India

J&J had earlier applied to the drug regulator seeking emergency use authorisation (EUA) for Covid-19 vaccines for adults.

India central drugs standard control organisationCentral drugs standard control organisationJohnson indiaEmergency use authorisationDrug controller generalJ ampj vaccineJohnson ampJ ampஇந்தியா மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந்மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந்ஜான்சன் இந்தியாமருந்து கட்டுப்படுத்தி ஜநரல்ஜான்சன் ஆம்ப்ஜு ஆம்ப்

Johnson & Johnson seeks regulator nod for vax trials in 12-17 age group in India

The American-based pharma major Johnson & Johnson (J&J) has applied to the Central Drugs Standard Control Organisation (CDSCO) for permission to conduct a vaccine trial of the Covid-19 single shot Janssen vaccine in India on children of .

United statesNew delhiMansukh mandaviyaSerum institute covishieldUnion healthCentral drugs standard control organisationEmergency use authorisationDrug controller generalJohnson indiaUnion health minister mansukh mandaviyaEmergency useNow indiaSerum instituteBharat biotechஒன்றுபட்டது மாநிலங்களில்புதியது டெல்ஹி

Enzene obtains marketing authorisation for Romiplostim Biosimilar drug in India

BioSpectrum is an integrated B2B media platform for the healthcare and bioscience industry in India and Asia.

Enzene romiplostimHimanshu gadgilEnzene biosciencesSandeep singhAlkem laboratoriesMarketing authorizationDrug controller generalImmune thrombocytopenic purpuraWhole time directorHealthcare managementLife sciencesUs healthcareAsia biotechஹிமான்ஷு காட்கில்சந்தீப் சிங்அல்கெம் ஆய்வகங்கள்

Enzene Biosciences Ltd obtains Marketing Authorization for its Romiplostim Biosimilar drug in India

Pune (Maharashtra) [India], August 20 (ANI/PRNewswire): Enzene Biosciences Ltd. "Enzene" announces a successful Marketing Authorization (MA) from the Drug Controller General of India (DCGI) for its second biosimilar drug "Romiplostim", indicated for the treatment of chronic Immune Thrombocytopenic Purpura (ITP) in adults.

Himanshu gadgilEnzene romiplostimSandeep singhAlkem laboratories ltdEnzene biosciences ltdEnzene biosciencesMarketing authorizationDrug controller generalImmune thrombocytopenic purpuraWhole time directorManaging directorDr himanshu gadgilBandeep singhStrategic partnershipsஹிமான்ஷு காட்கில்சந்தீப் சிங்